Copyright
©The Author(s) 2022.
World J Gastrointest Endosc. Jul 16, 2022; 14(7): 416-423
Published online Jul 16, 2022. doi: 10.4253/wjge.v14.i7.416
Published online Jul 16, 2022. doi: 10.4253/wjge.v14.i7.416
Table 4 List of antiangiogenic agents
| Anti-angiogenic agents (n = 60) | |
| Vascular-endothelial growth factor inhibitors | |
| 1 Bevacizumab | 30 |
| 2 Ramucirumab | 3 |
| 3 Lenvatinib | 4 |
| 4 Sorafenib | 2 |
| Epidermal-growth factor receptor inhibitors | |
| 1 Cetuximab | 3 |
| 2 Osimertinib | 1 |
| Tyrosine-kinase inhibitors | |
| 1 Lapatinib | 1 |
| 2 Pazopanib | 2 |
| 3 Imatinib | 7 |
| 4 Dasatinib | 1 |
| 5 Sunitinib | 2 |
| Mammalian target of rapamycin inhibitor | |
| 1 Everolimus | 2 |
| 2 Temsirolimus | 2 |
- Citation: Azam M, Hudgi A, Uy PP, Makhija J, Yap JEL. Safety of endoscopy in patients undergoing treatments with antiangiogenic agents: A 5-year retrospective review. World J Gastrointest Endosc 2022; 14(7): 416-423
- URL: https://www.wjgnet.com/1948-5190/full/v14/i7/416.htm
- DOI: https://dx.doi.org/10.4253/wjge.v14.i7.416